MeMed news
- Liaison Memed Bv is an immune system based protein signature test for distinguishing between bacterial and viral infections
- The test was developed following the licensing agreement signed with Memed as announced in September 2020
- The new test is available on the Liaison Xl platforms in countries that accept CE mark and U.S. food and drug administration clearance is planned for 2022
DiaSorin (FTSE MIB: DIA) and MeMed announc
MeMed today announced that it has been named by Fierce
Medtech as one of its ‘Fierce 15’ medical technology companies of 2021, designating it as one of the most promising private medtech companies in the industry.
MeMed is a leader in the emerging field of advanced host-response technologies with a portfolio of solutions designed to provide actionable insights for tough clinical dilemmas, aimed at improving patient outcomes. MeMed BV®, a test that enables physi
MeMed, a leader in host response technologies, today announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio.
MeMed’s technology suite decodes the body’s immune response within minutes, providing physi
- The study demonstrated the test’s high performance in distinguishing between bacterial and viral infection
- Incorporated a broad pediatric population presenting with fever without source and respiratory tract infection
- MeMed’s test outperformed existing biomarkers of infection
MeMed, a leader in the emerging field of advanced hostresponse technologies, today announces positive results from AutoPilot, a prospectiv